Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

Showing posts with label risk reduction. Show all posts
Showing posts with label risk reduction. Show all posts

21 August 2012

U.S. Preventive Services Task Force May Soon Make HIV Testing Routine

via the Huffington Post, by Salimah Ebrahim

Hiv Testing RoutineWASHINGTON, Aug 20 (Reuters) - A U.S. health panel may soon make HIV testing as standard a practice as checking cholesterol levels, a move that would fundamentally change how the virus is detected and treated.

The U.S. Preventive Services Task force, a government-backed group of clinicians and scientists, is expected to make a new recommendation on HIV screening available for public comment before the end of the year.

Health officials close to the panel, speaking on condition of anonymity, see it making a positive recommendation for routine screening, updating their current position, issued in 2005, which leaves the decision up to doctors.

Under President Barack Obama's healthcare law, passed in 2010, insurers are required to cover preventive services that are recommended by the task force.

"This would be one of those major sea changes ... moving away from what has been somewhat the segmentation of HIV - either by population, by geography," said Michael Kharfen, chief of community outreach for the Washington, D.C., Department of Health. Kharfen, who worked on the frontlines of the HIV epidemic in New York in the 1980s, recalls when the prognosis for the disease was "practically certain you were going to die.

"It still will take culture change for medical providers, but this will be a tremendous leap," he said

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

Three-quarters of clinicians in the US willing to prescribe early HIV treatment for the purpose of prevention

via aidsmap.com, by Michael Carter

There is an overwhelming consensus among clinicians who prescribe HIV treatment in the US that people who are taking antiretroviral therapy are less likely to transmit HIV to their sexual partners, according to results of a study published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Results also showed that over three-quarters of care providers would be willing to prescribe early therapy to people with an HIV-negative partner for the purposes of prevention.

The study involved 165 prescribing clinicians working at HIV clinics in the Bronx, New York, and Washington DC. It was conducted in 2010 and 2011, well before the publication of the results of the HPTN 052 study in the summer of 2012, which showed that virologically suppressive HIV treatment reduced the risk of transmission by 96%. US HIV treatment guidelines were updated in 2012 to endorse early treatment to reduce the risk of transmission.

“This survey of HIV clinicians in two US cities found most clinicians believe that ART [antiretroviral therapy] can reduce HIV transmission, even before the results of HPTN 052 demonstrated ART to be effective for this purpose, and before 2012 treatment guideline changes recommending ART for patients at risk for HIV transmission,” write the authors.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

15 August 2012

Newly infected individuals sustaining HIV epidemic in Geneva

via aidsmap, by Michael Carter

Individuals with recent HIV infection are sustaining the epidemic, a Swiss study published in the online edition of AIDS suggest. The investigators believe that their results further support the use of antiretroviral therapy as prevention, but also show that its impact on the epidemic will be blunted because of the high number of transmissions which can be attributed to individuals who have been recently infected with HIV and who are not yet taking treatment.

Phylogenetic analysis showed that only a handful of infections in individual diagnosed between 2008 and 2010 could be attributed to patients diagnosed before 2000. Patients with longer-term HIV infection were the group most likely to be taking antiretroviral therapy and to have an undetectable viral load.

“Recent HIV infections were a significant source of HIV spread,” comment the authors. “By contrast, HIV individuals diagnosed before 2000 were rarely the source of new infections before 2008.”

It is now widely accepted that patients who are taking HIV therapy that suppresses their viral load to undetectable levels are highly unlikely to transmit the virus to their sex partners.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

09 August 2012

CDC Issues Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults

via Morbidity and Mortality Weekly Report
In the United States, an estimated 48,100 new human immunodeficiency virus (HIV) infections occurred in 2009 (1). Of these, 27% were in heterosexual men and women who did not inject drugs, and 64% were in men who have sex with men (MSM), including 3% in MSM who inject drugs. In January 2011, following publication of evidence of safety and efficacy of daily oral tenofovir disoproxil fumarate 300 mg (TDF)/emtricitabine 200 mg (FTC) (Truvada, Gilead Sciences) as antiretroviral preexposure prophylaxis (PrEP) to reduce the risk for HIV acquisition among MSM in the iPrEx trial, CDC issued interim guidance to make available information and important initial cautions on the use of PrEP in this population.

Those recommendations remain valid for MSM, including MSM who also have sex with women (2). Since January 2011, data from studies of PrEP among heterosexual men and women have become available, and on July 16, 2012, the Food and Drug Administration (FDA) approved a label indication for reduction of risk for sexual acquisition of HIV infection among adults, including both heterosexuals and MSM.* This interim guidance includes consideration of the new information and addresses pregnancy and safety issues for heterosexually active adults at very high risk for sexual HIV acquisition that were not discussed in the previous interim guidance for the use of PrEP in MSM.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

20 July 2012

WHO issues first guidance on use of antiretrovirals by HIV-negative people at high risk to prevent infection


World Health Organization20 JULY 2012 | GENEVA / WASHINGTON DC - WHO has issued its first guidance to countries that are considering offering HIV medications, known as antiretrovirals (ARVs), to protect people who do not have the virus but who are at high risk of HIV infection.



Pre-exposure prophylaxis (PrEP):

The guidance is based on clinical trials indicating that a daily dose of oral antiretroviral medication, known as pre-exposure prophylaxis (PrEP), taken by HIV-negative people to reduce the risk of infection, is both safe for people to use and effective in preventing HIV. The iPrEX study shows that use of PrEP can reduce HIV infection by around 40% among men who have sex with men – and up to 73% among those who took the medicine regularly. The Partners PrEP study found 75% protection among serodiscordant couples (couples in which one person is HIV positive) in Kenya and Uganda.

The range of results in these studies highlight the potential benefits of PrEP, but also the importance of combining it with consistent use of condoms, as well as frequent HIV testing, counselling, and treatment of sexually transmitted infections.

They also emphasize the importance of taking medicines every day. Many people who are at high risk for HIV may not easily be able to incorporate the diligent treatment regimen required, so the next challenge is to ascertain how best to deliver PrEP to those who would benefit from it in ‘real life’ settings in order to achieve the necessary adherence and maximum public health gains.


PrEP projects in countries:

To better understand how PrEP can best contribute to a combination HIV prevention programme, WHO is encouraging countries wishing to introduce PrEP to first establish small projects to help public health workers to better understand and realize its potential benefits. In these projects, ARVs would be given to people at high risk of HIV infection. These could include uninfected men or transgender women who have sex with men who have a high risk of being HIV-positive. The aim is to identify which groups will benefit most from PrEP, and ascertain the best ways to deliver the services to them.

WHO will evaluate the outcome of these projects, together with the evolving scientific evidence. The results will help determine the best way to integrate PrEP guidance in future consolidated WHO guidelines on the use of antiretrovirals for preventing and treating HIV infection, which are expected in the summer of 2013.


Read the rest.



[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

19 July 2012

NIH to test maraviroc-based drug regimens for HIV prevention

via National Institute of Health


Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection.



The eventual goal is to see if the drug regimens can reduce the risk of infection.

The trial involves a strategy known as pre-exposure prophylaxis, or PrEP, in which HIV-uninfected individuals who are at risk for contracting the virus take one or two HIV drugs routinely in an effort to prevent infection. Called Novel Exploration of Therapeutics for PrEP, or NEXT-PrEP, the two-year study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"The NEXT-PrEP study will examine whether maraviroc-based PrEP is safe and well-tolerated. It is a necessary first step before we can test the effectiveness of maraviroc-based PrEP, and in the future, potentially expand the selection of drugs that may be used in this emerging HIV prevention strategy," said NIAID Director Anthony S. Fauci, M.D.

Led by principal investigator Roy M. Gulick, M.D., M.P.H., chief of the Division of Infectious Diseases and professor of medicine at Weill Cornell Medical College of Cornell University, the study team will enroll 400 HIV-uninfected men who have sex with men (MSM) ages 18 and older in 12 cities in the United States and Puerto Rico.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

18 July 2012

SA docs welcome US approval of ARV as a prevention tool

via health-e news, by Anso Thom


South African HIV Clinicians have welcomed an announcement that the Food and Drug Administration (FDA) in the United States has approved the use of an antiretroviral by sexually active HIV-negative men and women as a method of reducing the risk HIV infection in adults.

The debate around the use of ARVs as prevention surfaced several years ago with a number of studies showing it to be effective and safe. In what has been described a possibly a major turning point, the FDA announced this week that it had approved the use of tenofovir disproxil fumarate/emtricibatine (TDF/FTC), also known as Truvada, in HIV prevention.

TDF/FTC has been used to treat HIV infection since 2004, in combination with other antiretroviral drugs.

The FDA announcement means the pill can be taken by uninfected men and women a day before and after exposure (know as pre-exposure prophylaxis or PrEP).

Dr Francesca Conradie, president of the Southern African HIV Clinicians Society welcomed the announcement.

She said there was no one single answer to the prevention of HIV infection, no “one size fits all”.

 Read the rest.



[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

US approval of drug for HIV prevention welcomed cautiously in UK

via Pink News, by Stephen Gray

NAT said the drug would not take the place of condom use and education in mainstream prevention efforts (Photo: Karrie Nodalo)The decision by US authorities to approve the anti-retroviral drug Truvada for groups at risk of contracting HIV has been cautiously welcomed in the UK.

The US Food and Drug Administration approved Truvada for pre-exposure prophylaxis (PrEP), to help prevent HIV infection amongst those at very high risk.

the FDA emphasised the need for other prevention methods, such as safe sex practices, risk reduction counselling and regular HIV testing.

FDA commissioner Margaret A Hamburg said it was an “important milestone” in the fight against HIV.

She said: “Every year, about 50,000 US adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease.

“New treatments as well as prevention methods are needed to fight the HIV epidemic in this country.”

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

16 July 2012

FDA approves first drug for reducing the risk of sexually acquired HIV infection

via FDA

FDA News Release:

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

The FDA previously approved Truvada to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and children 12 years or older.

As part of PrEP, HIV-uninfected individuals who are at high risk will take Truvada daily to lower their chances of becoming infected with HIV should they be exposed to the virus. A PrEP indication means Truvada is approved for use as part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing.

"Today’s approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg, M.D. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease. New treatments as well as prevention methods are needed to fight the HIV epidemic in this country."

Read the rest here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

05 July 2012

Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study

[This is of great interest to the Mapping Pathways team as our work is quite similar. Very interesting!]


via British Medical Journal, by Ana Wheelock, Andreas B Eisingerich, Gabriela B Gomez, Emily Gray, Mark R Dybul, Peter Piot


Abstract

Objectives To examine policymakers and providers' views on pre-exposure prophylaxis (PrEP) and their willingness to support its introduction, to inform policy and practice in this emerging field.

Design Semistructured qualitative interview study.

Setting Peru, Ukraine, India, Kenya, Uganda, Botswana and South Africa.

Participants 35 policymakers, 35 healthcare workers and 21 non-governmental organisation representatives involved in HIV prevention.

Results Six themes emerged from the data: (1) perceived HIV prevention landscape: prevention initiatives needed to be improved and expanded; (2) PrEP awareness: 50 of 91 participants had heard of PrEP; (3) benefits of PrEP: one component of the combination prevention arsenal that could help prioritise HIV prevention, empower key populations and result in economic gains; (4) challenges of PrEP: regimen complexity, cost and cost-effectiveness, risk compensation, efficacy and effectiveness, stigmatisation and criminalisation, information and training and healthcare system capacity; (5) programmatic considerations: user eligibility, communication strategy, cost, distribution, medication and HIV testing compliance and (6) early versus late implementation: participants were divided as to whether they would support an early introduction of PrEP in their country or would prefer to wait until it has been successfully implemented in other countries, with around half of those we spoke to supporting each option. Very few said they would not support PrEP at all.

Conclusions Despite the multiple challenges identified, there was general willingness to support the introduction of PrEP. Yet, strengthening existing HIV prevention efforts was also deemed necessary. Our results suggest that an effective PrEP programme would be delivered in healthcare facilities and involve non-governmental organisations and the community and consider the needs of mobile populations. Comprehensive information packages and training for users and providers would be critical. The cost of PrEP would be affordable and possibly segmented. Extensive counselling and innovative monitoring measures ought to be considered.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

Addressing the structural drivers of HIV/AIDS: a luxury or necessity for programmes?

via Journal of the International AIDS Society, by Seeley J, Watts CH, Kippax S, Russell S, Heise L, Whiteside A.

Abstract

The social, economic, political and environmental structural factors that increase susceptibility to HIV infection and undermine prevention and treatment efforts continue to pose a challenge. The papers in this series highlight the importance of sustaining those efforts to address the structural drivers of the HIV epidemic, and that initiatives to achieve HIV elimination will only come about through a comprehensive HIV response, that includes meaningful responses to the social, political, economic and environmental factors that affect HIV risk and vulnerability. In the context of declining resources for HIV/AIDS, the papers speak to the need to integrate responses to the structural drivers of HIV/AIDS into future HIV investments, with both initiatives to integrate HIV into broader gender and development initiatives, as well as adaptations of current service models, to ensure that they are sensitive to and able to respond to the broader economic and social responsibilities that their clients face.

Access the free PDF here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

13 February 2012

WHO experts fail to agree on recommendations surrounding injectable contraceptives

via AllAfrica.com, by John Muchangi

Health experts have failed to agree on the use of injectable contraceptives, which were linked to increased HIV infections in Kenya. World Health Organisation said the decision will now be made when another team meets on February 15.

WHO had initially formed a team of 53 experts from 20 countries to review the research which revealed that injectable contraceptives like Depo Provera double the risk of contracting HIV.

Recommendations made by that team will now be assessed by the WHO Guidelines Review Committee - the body that oversees the production of WHO public health guidelines for countries. "The Committee will meet on 15 February and announce its recommendations the following day," said the organisation's spokeswoman Fadéla Chaib.

She insisted hormonal contraceptives and intrauterine devices known as IUDs do not offer any protection against HIV or other sexually transmitted infections. "Condoms are the mainstay of dual protection against both unwanted pregnancy and STIs including HIV," she said in a statement.

WHO's last guidance in 2009, based on the best evidence available at that time, said women at high risk of HIV infection and those living with HIV could safely use hormonal methods.

However, last year's study by the University of Washington, Kenyatta National Hospital, University of Nairobi and Moi University offered a different opinion. The study, published in The Lancet medical journal, revealed that injectables double the risk of women contracting HIV and also increase the risk of HIV-positive users infecting their male partners. It involved 3,800 couples from Kenya,Uganda, Tanzania, Botswana, Rwanda, South Africa and Zambia.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

23 January 2012

Separating the Smoke from the Fire: Lubricant Use and HIV


Original content from the Mapping Pathways blog team

The January 2012 issue of Sexually Transmitted Diseases – Journal of the American Transmitted Diseases Association has published data from a rectal health and behavior study whose findings “suggest some lubricant products may increase vulnerability to STIs”. The study concludes that “because of wide use of lubricants and their potential as carrier vehicles for microbicides, further research is essential to clarify if lubricant use poses a public health risk”. The paper has fueled a tremendous amount of discussion in HIV treatment and prevention communities around the world because such a link would have massive repercussions. Perhaps the title of the article also helped spark the dialogue: “The Slippery Slope: Lubricant Use and Rectal Sexually Transmitted Infections: A Newly Identified Risk”.

The questions are popping up quickly. What does this mean? Do we begin to alter strategies? Do we wait for conclusive proof? How will the layperson interpret this? Use lubricants or not? Which ones? Water-based? Silicone? Oil-based? Healthcare and advocacy professionals are wondering whether this will impact the messages they communicate to people. One discussion forum grappling with these issues is the membership listserv run by IRMA (International Rectal Microbicide Advocates). The listserv has been the site of a lively conversation among individuals from various countries. And this discussion has been ongoing for a few years. IRMA has a Lube Safety Working Group, and has some great resources on this issue via their blog.

“We need to be clear – there are only associations between lube use for anal intercourse and STDs. There is no proof that lube use causes increased risk. We simply don’t know that. Because we don't know, IRMA has long been advocating for a lube safety research agenda to fill in our gaps in the science and the evidence base,” says Jim Pickett, Director of Prevention Advocacy and Gay Men’s Health at the AIDS Foundation of Chicago, chair of IRMA, and a member of the Mapping Pathways team.

“Our key messages still hold true. 1) More research is urgently needed to explore if there is a link between lube use and acquiring HIV and/or rectal STIs. 2) It is unclear whether any particular type or brand of lube might increase, decrease, or have no effect on acquiring HIV and/or rectal STIs. 3) Using male or female condoms is still considered the best way to prevent acquiring HIV and STIs during anal intercourse. In addition, the use of condom-compatible lubes has been associated with a decreased risk of condoms breaking or slipping. 4) It is not possible at this time to recommend for or against using lubes if having anal intercourse without condoms. Lube use on its own is not a proven method of HIV or STI prevention,” explains Jim.

Read on for an interesting debate on various aspects of the study, prevention options, risk reduction, and risk elimination.

George Victor,  a Project Coordinator and health educator who works with men who have sex with men (MSM) and other minority groups, describes the strategy his team is following: “For now, the data we have indicates that unprotected anal sex carries the highest risk of HIV infection, that latex condoms should always be used correctly with water-based lubrication, and that the rectum has a higher concentration of CD4 cells and a larger surface area than the vagina – which means higher opportunities for infection. Therefore, correct and consistent use of condoms and water-based lubricants, together with quarterly HIV testing and STI screening and treatment is the best bet we have today.”

Paul Whannel, a communications coordinator with the AIDS Project of Central Iowa, made an interesting point saying, “I question why there’s not a third option: If an MSM is unwilling to use barriers, use silicone lube – it’s at least potentially safer than water-based... A growing segment of MSM will simply ‘check out’ if you're only willing to talk barrier use. Shouldn’t we be talking risk reduction with those guys?”

“Don't forget that many of us gals will simply ‘check out’ as well!” adds Carrie E. Foote, PhD, an Associate Professor of Sociology at Indiana University-Purdue University who has been living with HIV for over 20 years. “I suspect most women and their male partners (especially those who exclusively have sex with women) rarely get any messages at all about anal intercourse. It was nice to see that half the participants in the study were women.”

“Paul, I hear what you are saying and agree with you in principle. I think that for prevention purposes, however, the most effective mechanical methods of prevention would involve some sort of barrier,” responds George. “Having said that, I agree that choice is important. We don’t say to guys that they MUST use a condom and water-based lube. We have a discussion, conduct risk reduction and assessment, and find solutions that are locally available and practical. Our role is to provide information, support, and very importantly options.”

“As rectal microbicide advocates, our whole reason for being is to help serve those for whom condoms don't work (for whatever reason). We are interested in the research and development of safe, effective, acceptable and accessible rectal microbicides for those very people,” points out Jim. “However, I think it gets tricky when we get to making a recommendation regarding lube use as harm reduction (any kind) in the absence of data.”

“What does risk reduction mean anyway?” asks Aditya Bondyopadhyay, an HIV advocate working in India. “Is it not a fact that the only sure method of avoiding risk of infection is to consistently and correctly use a condom in every instance of penetrative anal sex? I feel the emphasis should stay here. Other ways can and should be in addition to this, not stand-alone.”

“The only really ‘sure method of avoiding risk of infection’ is abstinence from anal and oral intercourse – which could be classified as risk elimination,” says Mark Hubbard from Tennessee in the US. “That’s pretty useless for most of the adults we’re trying to reach; everything else, including the consistent use of condoms, is ‘risk reduction.’ The effectiveness of all risk reduction methods varies and is dependent on the user. ALL of these methods (including abstinence and condom use) have advantages and disadvantages that are very real, and vary from person to person.”

Doreen Hardy highlighted the need for a different type of data: “We need better behavioral data – exactly how are people having anal sex? There are so many variables to consider beyond latex and lubes – the degree of sphincter relaxation before penetration, sexual position, concomitant drug use, frequency, etc. Behavioral data could trump the lubricant data. It is such a difficult subject for sexuality educators because it is hard to build rationale with so little evidence. The default educator has become porn and frankly they do a terrible job. Their objective is to edit for arousal value (usually by eroticizing power) not educational value so a lot of people think furtive, hard, and fast anal sex is the norm. Now that it has become a common part of the sexual repertoire of Americans, I think people are willing to talk about it without having it be shrouded in homophobia.  Maybe someone can start with focus groups and move on to larger quantitative studies.”

“One striking thing is that this was mainly a study of people in committed relationships (56% of sex reported was with main partners) and not of casual sex. Casual/one-off sex only featured in less than 5% of encounters or 12% if you add in ‘acquaintances’. Most of the rest (83%) is between main or regular partners or ‘friends’. This makes the ‘the only thing we can say is to use condoms every time’ line even more incomplete as a response: We have to say it, but most research finds that condom use in long-term relationships, even serodiscordant ones, is an exception not a rule,” says a journalist specializing in HIV. “There are way too many uncertainties and confounders in this study to make any pronouncement on its basis … they didn't get into what people might be doing sexually that led them to choose one lube over another, or to use lube at all. I agree with Jim; we cannot make any recommendations about what lube to use on the basis of this study.”

A doctor summed up the overall mood perfectly at the end, “I'm thankful that a lot of the folks on this list are advocating for, conducting, and funding some of the very research we need to be able to answer the questions. I am awaiting the next wave of research with anticipation.”


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]